Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: azelaic acid gel 15% Clear all
Completed No phase listed Observational

Preferences & Treatment Satisfaction Drivers in Rosacea Patients

NCT02602470
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251), Azelaic Acid Cream, Metronidazole gel, Metronidazole cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 4 Interventional

Investigation of the Tolerability of Two Facial Cleansing Routines for Mild to Moderate Acne

NCT05446402
View directory record Official record
Conditions
Acne
Interventions
Geologie Acne Regimen - one side of face, Proactive Acne Regimen - other side of face
Combination Product
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional

Comparison of Efficacy and Safety of Azelaic Acid 15% Gel With Its Vehicle in Subjects With Mild to Moderate Acne

NCT00031096
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Azelaic Acid Gel 15% (Finacea, BAY39-6251), Vehicle gel (SH H 655 PBA)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
16
States / cities
Mobile, Alabama • Boulder, Colorado • Newnan, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Azelaic Acid Foam, 15% in Papulopustular Rosacea

NCT01257919
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic Acid Foam, Azelaic Acid Gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)

NCT01038869
View directory record Official record
Conditions
Acne Vulgaris, Post Inflammatory Hyperpigmentation
Interventions
Azelaic acid
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 6, 2026, 1:03 PM EDT
Not listed Phase 4 Interventional

Azelaic Acid Versus Hydroquinone in Melasma

NCT00927771
View directory record Official record
Conditions
Melanosis
Interventions
azelaic acid gel, hydroquinone cream
Drug
Lead sponsor
Callender Center for Clinical Research
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mitchellville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2009 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea

NCT02120924
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid, Vehicle, Finacea
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
30
States / cities
Fremont, California • Santa Monica, California • Brandon, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea

NCT00855595
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid (Finacea, BAY39-6251), Metronidazole (Metrogel), Doxycycline (Oracea)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
17
States / cities
Birmingham, Alabama • Denver, Colorado • West Palm Beach, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin

NCT01139047
View directory record Official record
Conditions
Skin Manifestations
Interventions
metronidazole 1% gel, azelaic acid 15% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01494467
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin

NCT01139008
View directory record Official record
Conditions
Skin Manifestations
Interventions
metronidazole 1% gel, azelaic acid 15% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Not applicable Interventional Results available

Combination Gel and Vascular ND in Mild to Moderate Rosacea

NCT01631656
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid, Nd:Yag laser
Drug · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 4 Interventional Results available

Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study

NCT02147691
View directory record Official record
Conditions
Acne Rosacea
Interventions
Azelaic acid 15%, Brimonidine 0.33%
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Azelaic Acid on Demodex Counts in Rosacea

NCT03035955
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 6, 2026, 1:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea

NCT01659853
View directory record Official record
Conditions
Erythema, Rosacea
Interventions
CD07805/47 gel 0.5%/CD07805/47 Vehicle, azelaic acid gel 15%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
4
States / cities
Evansville, Indiana • Louisville, Kentucky • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 6, 2026, 1:03 PM EDT